Myomar Molecular Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Myomar Molecular Inc. - overview
Established
2021
Location
Halifax, NS, Canada
Primary Industry
Biotechnology
About
Based in Nova Scotia, Canada, and co-founded by Rafaela Andrade (CEO) and Dylan Deska-Gauthier in 2021, Myomar Molecular Inc. operates as a biotechnology research company that develops diagnostic equipment for musculoskeletal disorders like muscle atrophy. In March 2024, the firm raised grant funding led by investors Government of Canada and Government of Nova Scotia. The company develops diagnostic equipment for musculoskeletal disorders like muscle atrophy.
Myomar Molecular utilizes the combination of molecular biomarkers of muscle metabolism to develop a Multiple Assay Test that allows individuals to track their muscle health using simple urine samples, similar to a home-pregnancy test. This user-friendly test provides accurate insights into muscle health, enabling individuals to monitor changes over time and share results with healthcare providers. The company plans to utilize the March 2024 funding to commercialize its muscle health monitoring device and hire additional operational staff.
Current Investors
Government of Canada, Government of Nova Scotia
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Diagnostic Equipment
Website
www.myomarmolecular.ca/
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.